Generalist · PE Firm
PSG Equity
Boston growth equity firm ($30B AUM) whose single quantum position is a massive one: lead of Quantum Machines' $170M Series C (Feb 2025), the largest control-layer bet in the industry. Software metrics first, qubits second.
Investment thesis
Growth equity pure-play in B2B software (founded 2014 as Providence Strategic Growth, independent since November 2020, $30B AUM at December 2025): backs companies past the inflection point, with proven product-market fit and rapid organic growth, never science risk ($10M-$150M checks).
'Small software at scale': lower-middle-market entry, then transformation through add-on acquisitions (530+ facilitated) and operational playbooks (Value Creation Initiatives).
Quantum entered the thesis through the software door: Quantum Machines is the control layer used by more than half of all quantum computer builders, a picks-and-shovels infrastructure business with recurring commercial traction, not a qubit bet. PSG led its $170M Series C in February 2025, with Director Rotem Shacham joining the board.
The Tel Aviv office (opened 2021, Ronen Nir and Rotem Shacham, both ex-Viola) is the deal engine for Israeli deep-tech-flavored software, and sourced the QM lead.
Anti-thesis
The patterns that trigger a fast no with this fund.
- One quantum deal in 12 years across ~170 companies: no published quantum thesis, no second deal detected by June 2026. If your profile is not QM-like (real recurring revenue, industry-wide customer base, infrastructure position), PSG is not your door
- Growth equity, not venture: pre-revenue, risky hardware, low TRL = out of scope. PSG requires demonstrated product-market fit and rapid organic growth (their own language)
- Majority/buy-and-build playbook: a quantum founder seeking a passive minority check with light governance will find the PSG culture (VCIs, add-ons, EBITDA optimization) invasive
- QM was a profile anomaly (control layer sold to over 50% of the industry): do not extrapolate a generalized quantum appetite